Literature DB >> 12595456

CD40-CD40 ligand costimulation is not required for initiation and maintenance of a Th1-type response to Leishmania major infection.

Udaikumar M Padigel1, Jay P Farrell.   

Abstract

Although previous studies demonstrated a requirement for CD40-CD40 ligand (CD40L) interaction in the development of resistance to Leishmania infection, we recently showed that mice lacking the gene for CD40L (CD40L(-/-) mice) can control Leishmania major infection when they are infected with reduced numbers of parasites. In this study, we examine the cytokine pattern in healing versus nonhealing CD40L(-/-) mice and investigated whether CD40 activation is required for resistance to reinfection. We observed that CD4(+) cells in healed CD40L(-/-) mice produce high levels of gamma interferon compared to cells from nonhealing, high-dose-inoculated mice. In addition, we observed a higher frequency of interleukin-12 (IL-12)- producing cells and a reduced number of IL-4-producing cells in mice infected with reduced numbers of parasites. Importantly, we found that healed CD40L(-/-) mice are highly resistant to reinfection with a large parasite inoculum. In addition, by comparing the cytokine patterns at an early and late stage of infection in nonhealing CD40L(-/-) mice, we demonstrated that nonhealing CD40L(-/-) mice produce a weak Th1-type response during the early stage of infection, but this response wanes as a Th2-type response emerges during late stages of infection. Anti-IL-4 antibody treatment, starting either at the beginning of infection or at week 4 postinfection enabled CD40L(-/-) mice to control a high-dose infection. Together, these results show that CD40-CD40L interaction, although important for IL-12 production in high-dose infections, is not required for either the development or maintenance of resistance in mice infected with reduced numbers of parasites.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595456      PMCID: PMC148881          DOI: 10.1128/IAI.71.3.1389-1395.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  The development of a Th1-type response and resistance to Leishmania major infection in the absence of CD40-CD40L costimulation.

Authors:  U M Padigel; P J Perrin; J P Farrell
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

2.  CD28 costimulation and parasite dose combine to influence the susceptibility of BALB/c mice to infection with Leishmania major.

Authors:  Helen L Compton; Jay P Farrell
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

3.  IL-13 is a susceptibility factor for Leishmania major infection.

Authors:  D J Matthews; C L Emson; G J McKenzie; H E Jolin; J M Blackwell; A N McKenzie
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

4.  Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF.

Authors:  P Wilhelm; U Ritter; S Labbow; N Donhauser; M Röllinghoff; C Bogdan; H Körner
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

5.  The roles of CD28 and CD40 ligand in T cell activation and tolerance.

Authors:  K C Howland; L J Ausubel; C A London; A K Abbas
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

6.  In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease.

Authors:  H Himmelrich; P Launois; I Maillard; T Biedermann; F Tacchini-Cottier; R M Locksley; M Röcken; J A Louis
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

7.  IL-12 is required to maintain a Th1 response during Leishmania major infection.

Authors:  A Y Park; B D Hondowicz; P Scott
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

8.  Vaccination against the intracellular pathogens Leishmania major and L. amazonensis by directing CD40 ligand to macrophages.

Authors:  G Chen; P A Darrah; D M Mosser
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  Interleukin-4 receptor alpha-deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection.

Authors:  M Mohrs; C Holscher; F Brombacher
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

10.  Recombinant interleukin 12 cures mice infected with Leishmania major.

Authors:  F P Heinzel; D S Schoenhaut; R M Rerko; L E Rosser; M K Gately
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more
  6 in total

1.  Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression.

Authors:  Jianguo Liu; Shanjin Cao; Sunjung Kim; Elaine Y Chung; Yoichiro Homma; Xiuqin Guan; Violeta Jimenez; Xiaojing Ma
Journal:  Curr Immunol Rev       Date:  2005-06

2.  Visceral Leishmaniasis May Unmask X-linked Hyper-IgM Syndrome.

Authors:  Luis Ignacio Gonzalez-Granado; Nerea Dominguez-Pinilla; Fernando Gallego-Bustos; Jesús Ruiz-Contreras; Luis M Allende
Journal:  J Clin Immunol       Date:  2016-03-17       Impact factor: 8.317

3.  In the absence of CD154, administration of interleukin-12 restores Th1 responses but not protective immunity to Schistosoma mansoni.

Authors:  James P Hewitson; Paul A Hamblin; Adrian P Mountford
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

Review 4.  CD40 and the immune response to parasitic infections.

Authors:  Carlos S Subauste
Journal:  Semin Immunol       Date:  2009-07-18       Impact factor: 11.130

5.  IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c⁺ cell populations during visceral leishmaniasis.

Authors:  Benjamin M J Owens; Lynette Beattie; John W J Moore; Najmeeyah Brown; Jason L Mann; Jane E Dalton; Asher Maroof; Paul M Kaye
Journal:  PLoS Pathog       Date:  2012-07-26       Impact factor: 6.823

6.  T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?

Authors:  James Alexander; Frank Brombacher
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.